Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.59 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | CHRNB1 | P11230 | 5/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.53 |
| ▸ | CHRNB3 | Q05901 | 5/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253030 | 1.00 | HTR6 (0.59) | HTR6HTR1DCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL7253026 | 1.00 | HTR6 (0.59) | HTR6HTR1DCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL7252913 | 0.78 | HTR7 (0.59) | HTR6HTR1DCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL7252917 | 0.78 | HTR7 (0.59) | HTR6HTR1DCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL7253243 | 0.77 | HTR6 (0.60) | HTR6HTR1DCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL7253245 | 0.77 | HTR6 (0.60) | HTR6HTR1DCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL7253405 | 0.76 | HTR6 (0.67) | HTR6 | |
| SCHEMBL7256599 | 0.76 | HTR6 (0.67) | HTR6 | |
| SCHEMBL7253410 | 0.76 | HTR6 (0.67) | HTR6 | |
| SCHEMBL7699226 | 0.75 | HTR7 (0.58) | HTR6HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | HTR6 368/4885HTR1D 128/4885CHRNB1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.